$2.63
0.77% yesterday
Nasdaq, Apr 28, 10:17 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Target price 2025 - Analyst rating & recommendation

ImmunityBio Inc Classifications & Recommendation:

Buy
80%
Hold
20%

ImmunityBio Inc Price Target

Target Price $11.25
Price $2.63
Potential
Number of Estimates 5
5 Analysts have issued a price target ImmunityBio Inc 2026 . The average ImmunityBio Inc target price is $11.25. This is higher than the current stock price. The highest price target is
$30.00 1,040.68%
register free of charge
, the lowest is .
A rating was issued by 5 analysts: 4 Analysts recommend ImmunityBio Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ImmunityBio Inc stock has an average upside potential 2026 of . Most analysts recommend the ImmunityBio Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 14.75 98.20
2,279.03% 565.77%
Net Margin -3,584.40% -425.31%
97.73% 88.13%

5 Analysts have issued a sales forecast ImmunityBio Inc 2025 . The average ImmunityBio Inc sales estimate is

$98.2m
Unlock
. This is
565.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$124m 740.68%
Unlock
, the lowest is
$85.4m 478.86%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $14.8m 2,279.03%
2025
$98.2m 565.77%
Unlock
2026
$269m 173.49%
Unlock
2027
$636m 136.83%
Unlock
2028
$1.4b 116.58%
Unlock
2029
$2.5b 83.84%
Unlock

5 ImmunityBio Inc Analysts have issued a net profit forecast 2025. The average ImmunityBio Inc net profit estimate is

$-418m
Unlock
. This is
22.26% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-358m 33.33%
Unlock
, the lowest is
$-494m 8.11%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-529m 46.09%
2025
$-418m 21.00%
Unlock
2026
$-246m 41.10%
Unlock
2027
$47.5m 119.31%
Unlock
2028
$516m 986.65%
Unlock
2029
$1.3b 146.16%
Unlock

Net Margin

2024 -3,584.40% 97.73%
2025
-425.31% 88.13%
Unlock
2026
-91.60% 78.46%
Unlock
2027
7.47% 108.16%
Unlock
2028
37.47% 401.61%
Unlock
2029
50.17% 33.89%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.62 -0.49
46.09% 20.97%
P/E negative
EV/Sales 30.16

5 Analysts have issued a ImmunityBio Inc forecast for earnings per share. The average ImmunityBio Inc EPS is

$-0.49
Unlock
. This is
22.22% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.42 33.33%
Unlock
, the lowest is
$-0.58 7.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.62 46.09%
2025
$-0.49 20.97%
Unlock
2026
$-0.29 40.82%
Unlock
2027
$0.06 120.69%
Unlock
2028
$0.61 916.67%
Unlock
2029
$1.49 144.26%
Unlock

P/E ratio

Current -4.16 36.20%
2025
-5.37 29.09%
Unlock
2026
-9.12 69.83%
Unlock
2027
47.22 617.76%
Unlock
2028
4.34 90.81%
Unlock
2029
1.77 59.22%
Unlock

Based on analysts' sales estimates for 2025, the ImmunityBio Inc stock is valued at an EV/Sales of

30.16
Unlock
and an P/S ratio of
23.63
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 200.80 97.77%
2025
30.16 84.98%
Unlock
2026
11.03 63.44%
Unlock
2027
4.66 57.78%
Unlock
2028
2.15 53.83%
Unlock
2029
1.17 45.60%
Unlock

P/S ratio

Current 157.35 98.03%
2025
23.63 84.98%
Unlock
2026
8.64 63.44%
Unlock
2027
3.65 57.78%
Unlock
2028
1.68 53.83%
Unlock
2029
0.92 45.60%
Unlock

Current ImmunityBio Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Apr 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 28 2025
D. Boral Capital
Locked
Locked
Locked Apr 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 16 2025
D. Boral Capital
Locked
Locked
Locked Apr 15 2025
D. Boral Capital
Locked
Locked
Locked Apr 09 2025
D. Boral Capital
Locked
Locked
Locked Mar 31 2025
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Apr 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 28 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 16 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 15 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 09 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 31 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today